In this study, we investigated quantity and quality of CD8+ T cell responses associated with anti-PD-L1 antibody (atezolizumab) treatment in PBMCs from NSCLC patients using mass cytometry and highly-multiplexed combinatorial tetramer staining to longitudinally monitor neoantigen-specific CD8+ T cells in patients with partial response or progressive disease upon treatment. This evidence concerns the gene CD8A and non-small cell lung carcinoma.